Engineered immune cells take on tough leukemia
NCT ID NCT02146924
First seen Jan 05, 2026 · Last updated May 12, 2026 · Updated 17 times
Summary
This early-stage study tests a new cellular therapy for adults with high-risk acute lymphoblastic leukemia (ALL) that has come back or not responded to treatment. Researchers take a patient's own white blood cells, add a gene to help them recognize and attack cancer cells, and infuse them back after chemotherapy. The main goals are to find the safest dose and understand side effects, while also checking if the treatment can reduce or eliminate leukemia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.